Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Alpha-GPC | Vinpocetine | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 300-600 mg/day | 5-20 mg 2-3 times daily (15-60 mg/day total) |
| Timing | Morning or pre-workout. Can be taken with or without food. Split into 1-2 doses. | With food (bioavailability increases 60-100% with food). Split into 2-3 doses due to short half-life (~2-3 hours). |
| Cycle Duration | Ongoing; no cycling required for standard doses | Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment. Clinical trials typically run 12-16 weeks. |
| Evidence Level | strong_human | moderate_human |
Highly bioavailable choline source that crosses the blood-brain barrier efficiently via passive diffusion. Serves as a direct precursor for acetylcholine synthesis and phosphatidylcholine, a major structural component of neuronal membranes. Also stimulates growth hormone release via cholinergic activation of GHRH-releasing neurons in the hypothalamus. Contains ~40% choline by weight.
300-600 mg/day
Morning or pre-workout. Can be taken with or without food. Split into 1-2 doses.
Ongoing; no cycling required for standard doses
Semi-synthetic derivative of vincamine (from Vinca minor/periwinkle) that selectively inhibits phosphodiesterase type 1 (PDE1) in cerebral vasculature, increasing cAMP and cGMP levels to promote vasodilation and restore regional cerebral blood flow without significant systemic blood pressure effects. Reduces intracellular calcium in smooth muscle cells and neurons. Inhibits voltage-gated sodium channels, providing neuroprotection against excitotoxicity. Potent anti-inflammatory agent via direct inhibition of IKK, attenuating NF-kB signaling. Downstream CREB and SRF phosphorylation promotes expression of plasticity-related genes.
5-20 mg 2-3 times daily (15-60 mg/day total)
With food (bioavailability increases 60-100% with food). Split into 2-3 doses due to short half-life (~2-3 hours).
Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment. Clinical trials typically run 12-16 weeks.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →